Exagen Inc. (NASDAQ:XGN), a provider of autoimmune disease testing, reported financial results for the fourth quarter and full year ended December 31, 2025. The company highlighted record annual revenue and growth in its core testing business, though its bottom-line results presented a mixed picture relative to analyst expectations.
Earnings and Revenue Versus Estimates
The company's fourth-quarter performance narrowly missed revenue expectations while its loss per share was slightly wider than anticipated.
- Q4 2025 Revenue: $16.63 million vs. Analyst Estimate: $16.73 million
- Q4 2025 EPS (Non-GAAP): -$0.20 vs. Analyst Estimate: -$0.19
For the full year 2025, Exagen reported total revenue of $66.58 million, representing a 20% increase over the prior year. This growth was driven by a combination of higher test volumes and an improved average selling price (ASP) for its flagship AVISE CTD test.
Market Reaction
The immediate market reaction to the earnings release appears muted to slightly negative. In pre-market trading following the report, the stock showed modest movement. This tepid response likely reflects the slight miss on both top and bottom-line estimates for the quarter, offset by the positive full-year growth narrative and a strengthened balance sheet.
Key Highlights from the 2025 Report
Beyond the quarterly earnings figures, Exagen's press release emphasized several operational and financial achievements for the full year:
- Volume and Price Growth: AVISE CTD test volume grew over 11% compared to 2024, while the trailing twelve-month average selling price increased 7% to $441 per test.
- Product Development: The company commercially launched novel biomarkers for seronegative rheumatoid arthritis, enhancing its testing platform.
- Financial Position: Exagen ended the year with $32.2 million in cash and cash equivalents, bolstered by a $20 million public offering and a $25 million credit facility secured during the year. Management stated this positions the company on its "path to cash flow positivity."
- 2026 Outlook: The company provided full-year 2026 revenue guidance in the range of $70 million to $73 million. This outlook sits just below the current analyst consensus estimate for 2026 sales of approximately $74.9 million.
Looking Ahead
Exagen's results paint a picture of a company executing on a turnaround, demonstrating solid top-line growth and operational improvements. However, the journey to profitability continues, as evidenced by the ongoing net losses. The company's provided revenue guidance for 2026, while indicating continued growth, suggests a more conservative trajectory than the market currently expects. Investors will be watching closely for progress in expanding test adoption, maintaining pricing strength, and moving toward the stated goal of cash flow positivity.
For a detailed look at Exagen's historical earnings and future analyst projections, you can review the data here. Additional analyst ratings and forecasts are available here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
